▎ 摘　　要

NOVELTY - Dual-targeted amphiphilic glycan derivative carrier (I) is new. The molecular weight of the glycan is 1500-150000 Da. The acid anhydride is succinic anhydride, glutaric anhydride or adipic anhydride. USE - (I) is useful: in medicinal composition for mild photothermal therapy of tumors; in medicinal composition for preparing antitumor medicine for cancer tumors including breast tumors, pancreatic tumors, ovarian tumors, esophageal tumors, liver tumors, biliary tumors, bladder tumors, colorectal tumors, prostate tumors and brain tumors (all claimed). ADVANTAGE - (I): can self-assemble into nanomicelles in water, and physically load photothermal conversion properties (PTA) and autophagy inhibitors for tumor photothermal therapy; has the ability of active dual targeting of tumor cells and tumor-related fibroblasts, and can efficiently enter the interior of cells through the action of receptor ligands to improve the transport efficiency of preparations; under the irradiation of 808nm laser, the absorbed light energy of PTA is efficiently converted into heat, and the autophagy inhibitor inhibits the autophagy behavior of tumor cells and sensitizes the photothermal, achieving superior mild photothermal treatment effect, which can weaken the physical barrier of the tumor matrix; involves tumor photothermal therapy, which can further induce immunogenic cell death of tumor cells, and the generated tumor fragments can further activate the immune system and greatly improve the effect of tumor photothermal therapy. DETAILED DESCRIPTION - Dual-targeted amphiphilic glycan derivative carrier of formula (I) is new. The molecular weight of the glycan is 1500-150000 Da. The acid anhydride is succinic anhydride, glutaric anhydride or adipic anhydride. R1 = 4-methoxybenzamide derivative of formula (II); R2 = hydmaterialrophobic group, preferably 8-18C fatty amine or 8-18C amine derivative of fatty acid, stearic acid or deoxycholic acid; n = 2,3 or 4; m = 10-926; y = number of repeating units of the acid anhydride modified segment, and the degree of substitution calculated according to y/m ranging from 10-50%; x = the number of repeating units of the target modified segment of the anisamide derivative, and the degree of substitution calculated according to x/m ranging from 1-10%; ubstitution degree of the hydroxy or hydrophobic segment = 4-40%; z = 1 or 2. INDEPENDENT CLAIMS are also included for: (1) Medicinal composition for mild photothermal therapy of tumors, comprising (I), a material with photothermal conversion properties and an autophagy inhibitor; (2) Preparing medicinal composition, comprising (1) performing esterification reaction of hydroxy end of the hydrophilic glucan and the acid anhydride under the action of a catalyst to obtain a partially carboxylated glucan intermediate, (2) subjecting the carboxy group of the carboxylated glucan intermediate and the amino group at one end of the hydrophobic group molecule to an amidation reaction under the action of a catalyst to obtain an amphiphilic glucan derivative carrier, (3) carrying out amidation reaction of benzoyl chloride and amine to obtain a benzamide derivative target, (4) performing amidation reaction of segment of carboxy group in the amphiphilic glucan derivative carrier and the amino group at one end of the benzamide derivative under the action of a catalyst to obtain a double-targeted amphiphilic glucan derivative support, (5) dissolving the dual-targeted amphiphilic dextran derivative carrier in water to obtain a nanomicelle solution, (6) dissolving the materials with photothermal conversion properties and autophagy inhibitors in organic solvent and then slowly adding dropwise to the nanoparticle solution, and subjecting to ultrasonic or high pressure homogenization, removing the organic solvent and free medicine by dialysis and centrifugation to obtain final product.